Modern treatment of pulmonary embolism

European Respiratory Journal, Supplement

Volumn 19, Issue 35, 2002, Pages

  Goldhaber, S Z ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Deep vein thrombosis; Embolectomy; Pulmonary embolism; Thrombolysis

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; THROMBIN INHIBITOR; TINZAPARIN; TROPONIN; WARFARIN; XIMELAGATRAN;

ADULT; AGED; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EMBOLECTOMY; HEART INFARCTION; HEART INJURY; HEART RIGHT BUNDLE BRANCH BLOCK; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HIGH RISK PATIENT; HUMAN; HYPOKINESIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; T WAVE; ACUTE DISEASE; FIBRINOLYTIC THERAPY; REVIEW; RISK ASSESSMENT;

ACUTE DISEASE; ANTICOAGULANTS; EMBOLECTOMY; HUMANS; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTORS; THROMBOLYTIC THERAPY;

EID: 0036479365     PISSN: 09041850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389.
2. Nakamura M, Fujioka H, Yamada N, et al. Clinical characteristics of acute pulmonary thromboembolism in Japan: results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol 2001; 24: 132-138.
3. Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000; 84: 548-552.
4. Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000; 101: 2817-2822.
5. Meyer T, Binder L, Hruska N, Luthe H, Buchwald AB. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 2000; 36: 1632-1636.
6. Giannitsis E, Muller-Bardorff M, Kurowski V, et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000; 102: 211-217.
7. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right ventricular function and pulmonary perfusion. Lancet 1993; 341: 507-511.
8. Nass N, McConnell MV, Goldhaber SZ, Chyu S, Solomon SD. Recovery of regional right ventricular function after thrombolysis for pulmonary embolism. Am J Cardiol 1999; 83: 804-806.
9. Kanter DS, Mikkola KM, Patel SR, Parker JA, Goldhaber SZ. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997; 111: 1241-1245.
10. Meyer G, Gisselbrecht M, Diehl JL, Journois D, Sors H. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Am J Med 1998; 105: 472-477.
11. Goldhaber SZ, Vaughan DE, Markis JE, et al. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 1986; 2: 886-889.
12. Goldhaber SZ, Kessler CM, Heit J, et al. A randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; 2: 293-298.
13. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 1992; 20: 24-30.
14. Goldhaber SZ, Agnelli G, Levine MN, on behalf of the Bolus Alteplase Pulmonary Embolism Group. Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. Chest 1994; 106: 718-724.
15. Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Increasing age is a major risk factor for hemorrhagic complications following pulmonary embolism thrombolysis. Am Heart J 1997; 134: 69-72.
16. Goldhaber SZ. Integration of catheter thrombectomy into our armamentarium to treat acute pulmonary embolism. Chest 1998; 114: 1237-1238.
17. Fava M, Loyola S, Huete I. Massive pulmonary embolism: treatment with the hydrolyser thrombectomy catheter. J Vasc Interv Radiol 2000; 11: 1159-1164.
18. Ullmann M, Hemmer W, Hannekum A. The urgent pulmonary embolectomy: mechanical resuscitation in the operating theatre determines the outcome. Thorac Cardiovasc Surg 1999; 47: 5-8.
19. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338: 409-415.
20. White RH, Zhou H, Kim J, Romano PS. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med 2000; 160: 2033-2041.
21. Agnelli G, Iorio A, Renga C, et al. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation 1995; 92: 2819-2824.
22. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.
23. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997; 337: 663-669.
24. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332: 1661-1665.
25. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anti-coagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907.
26. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345: 165-169.
27. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103: 2453-2460.
28. Ridker PM. Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial. Vasc Med 1998; 3: 67-73.
29. Ridker PM. Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosis. Curr Cardiol Rep 1999; 1: 88-90.
30. Blake GJ, Ridker PM. Optimal duration of anti-coagulation following venous thromboembolism among patients with and without inherited thrombophilia. In: Goldhaber SZ, Ridker PM, eds. Thrombosis and Thromboembolism. New York, Marcel Dekker, 2002; pp. 261-282.